This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem To Present At Multiple February Conferences

NEW YORK, Feb. 3, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple conferences in February.

BIO CEO 2014

  • Date and Time: Monday, February 10, 2014, 1:00 PM EST
  • Venue: The Waldorf Astoria, New York, New York
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem

New York Stem Cell Summit 2014

  • Date: Tuesday, February 18, 2014
  • Venue: The Convene, Downtown, New York, New York
  • Session #1 Time: 11:00 AM EST
  • Session #1 Topic: Treating the Aging Patient With Stem Cells
  • Session #1 Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem
  • Session #2 Time: 3:36 PM EST
  • Session #2 Topic: Cutting Time to Market for Stem Cell Suppliers
  • Session #2 Speaker: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT

GTC Cell & Gene Therapy Conference

  • Venue: Hyatt Regency Mission Bay, San Diego, California
  • Session #1 Date and Time: Thursday, February 20, 2014, 1:30 PM PST
  • Panel Topic: Emerging Technologies
  • Panel Moderator: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT
  • Session #1 Topic: The Emerging Technology is Intrinsic Biotechnology
  • Session #1 Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and New Technologies of NeoStem
  • Session #2 Date and Time: Friday, February 21, 2014, 1:40 PM PST
  • Panel Topic: Strategies for Commercialization
  • Panel Moderator: Robert A. Preti, PhD, Chief Scientific Officer of NeoStem and PCT and President of PCT
  • Session #2 Topic: Considerations for a Commercially Successful Cell Therapy Product
  • Session #2 Speaker: Sanjin Zvonic, PhD, Director, Technology & Business Development, PCT

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs